NCT00780117

Brief Summary

Contribute to support hypothesis of relationships between genes involve in oncogenesis and those involve in embryological development.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
57

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jun 2008

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2008

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

October 24, 2008

Completed
3 days until next milestone

First Posted

Study publicly available on registry

October 27, 2008

Completed
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2011

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2011

Completed
Last Updated

March 31, 2026

Status Verified

March 1, 2026

Enrollment Period

3 years

First QC Date

October 24, 2008

Last Update Submit

March 26, 2026

Conditions

CURRARINO SyndromeSacrococcygeal TeratomaPresacral Mass

Keywords

CURRARINO syndromeSacrococcygeal teratomaHLXB9 (MNX1) geneAlpha foeto proteinPrognosis factors

Outcome Measures

Primary Outcomes (1)

  • Annual lumbar-sacral MRI is performed

    one year

Secondary Outcomes (2)

  • Pathological tumoral tissue analysis after surgical removal

    3 years

  • Annual serum alpha-foeto protein level monitoring

    one year

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

specialized consultations in the currarino syndrom network

You may qualify if:

  • At least 1 out of the 4 major signs of CURRARINO syndrome:
  • Sacral agenesis
  • Hindgut malformation or chronic constipation
  • Presacral tumor and/or
  • TETHECORD syndrome and/or lipoma of the filum or the conus
  • Anomaly genotyping HLXB9 without clinical expression

You may not qualify if:

  • \- Opposition to sign informed consent agreement

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hôpital Necker-Enfants Malades Pediatric Surgery Department

Paris, 75015, France

Location

Biospecimen

Retention: SAMPLES WITH DNA

Pathological tumoral tissue analysis after surgical removal · Annual serum alpha-foeto protein level monitoring

MeSH Terms

Conditions

Currarino triad

Study Officials

  • Celia CRETOLLE, MD, PhD

    Assistance Publique Hopitaux de Paris

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 24, 2008

First Posted

October 27, 2008

Study Start

June 1, 2008

Primary Completion

June 1, 2011

Study Completion

December 1, 2011

Last Updated

March 31, 2026

Record last verified: 2026-03

Locations

FR(1)